February 15, 2026
Headlines

Keros Therapeutics Loses 75% Value In A Single Session – Here’s Why

01 mins

Keros Therapeutics halts high-dose cibotercept treatment in the TROPOS trial after safety concerns, with topline results anticipated in Q2 2025.

read more

Leave a Reply

Your email address will not be published. Required fields are marked *

Related News